
Sign up to save your podcasts
Or


CEO Jane Osbourn describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand why, and discusses this week's deal and the company's prior one with Lilly as well.
By BiotechTV4.3
66 ratings
CEO Jane Osbourn describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand why, and discusses this week's deal and the company's prior one with Lilly as well.

3,222 Listeners

1,910 Listeners

124 Listeners

324 Listeners

61 Listeners

9,957 Listeners

86 Listeners

34 Listeners

353 Listeners

19 Listeners

60 Listeners

512 Listeners

41 Listeners

0 Listeners

4 Listeners

2 Listeners

6 Listeners

48 Listeners